全文获取类型
收费全文 | 5127篇 |
免费 | 478篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 232篇 |
妇产科学 | 52篇 |
基础医学 | 660篇 |
口腔科学 | 300篇 |
临床医学 | 562篇 |
内科学 | 985篇 |
皮肤病学 | 182篇 |
神经病学 | 392篇 |
特种医学 | 298篇 |
外科学 | 800篇 |
综合类 | 49篇 |
预防医学 | 285篇 |
眼科学 | 51篇 |
药学 | 508篇 |
中国医学 | 7篇 |
肿瘤学 | 230篇 |
出版年
2022年 | 29篇 |
2021年 | 68篇 |
2020年 | 68篇 |
2019年 | 71篇 |
2018年 | 149篇 |
2017年 | 107篇 |
2016年 | 122篇 |
2015年 | 132篇 |
2014年 | 196篇 |
2013年 | 257篇 |
2012年 | 240篇 |
2011年 | 189篇 |
2010年 | 180篇 |
2009年 | 187篇 |
2008年 | 167篇 |
2007年 | 216篇 |
2006年 | 232篇 |
2005年 | 169篇 |
2004年 | 167篇 |
2003年 | 166篇 |
2002年 | 150篇 |
2001年 | 146篇 |
2000年 | 139篇 |
1999年 | 156篇 |
1998年 | 150篇 |
1997年 | 133篇 |
1996年 | 133篇 |
1995年 | 98篇 |
1994年 | 109篇 |
1993年 | 73篇 |
1992年 | 107篇 |
1991年 | 99篇 |
1990年 | 72篇 |
1989年 | 88篇 |
1988年 | 107篇 |
1987年 | 84篇 |
1986年 | 88篇 |
1985年 | 81篇 |
1984年 | 41篇 |
1983年 | 39篇 |
1982年 | 46篇 |
1981年 | 40篇 |
1980年 | 37篇 |
1979年 | 38篇 |
1978年 | 28篇 |
1977年 | 27篇 |
1976年 | 21篇 |
1975年 | 37篇 |
1974年 | 21篇 |
1973年 | 30篇 |
排序方式: 共有5634条查询结果,搜索用时 15 毫秒
1.
2.
3.
Yoshiki Imamura Takahiro Shinozaki Akiko Okada‐Ogawa Noboru Noma Masahiro Shinoda Koichi Iwata Akihiko Wada Osamu Abe Kelun Wang Peter Svensson 《Journal of oral rehabilitation》2019,46(6):574-587
Burning mouth syndrome (BMS) is a chronic oro‐facial pain disorder of unknown cause. It is more common in peri‐ and post‐menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS appear to be predisposed towards anxiety and depression. Atrophy of small nerve fibres in the tongue epithelium has been reported, and potential neuropathic mechanisms for BMS are now widely investigated. Historically, BMS was thought to comprise endocrinological, psychosocial and neuropathic components. Neuroprotective steroids and glial cell line–derived neurotrophic factor family ligands may have pivotal roles in the peripheral mechanisms associated with atrophy of small nerve fibres. Denervation of chorda tympani nerve fibres that innervate fungiform buds leads to alternative trigeminal innervation, which results in dysgeusia and burning pain when eating hot foods. With regard to the central mechanism of BMS, depletion of neuroprotective steroids alters the brain network–related mood and pain modulation. Peripheral mechanistic studies support the use of topical clonazepam and capsaicin for the management of BMS, and some evidence supports the use of cognitive behavioural therapy. Hormone replacement therapy may address the causes of BMS, although adverse effects prevent its use as a first‐line treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may have important benefits, and well‐designed controlled studies are expected. Other treatment options to be investigated include brain stimulation and TSPO (translocator protein 18 kDa) ligands. 相似文献
4.
5.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
6.
7.
Background
A standardised suction technique has been used to sample plasma proteins in dermal interstitial fluid (IF) serially for 5 to 6 days from a suction-induced skin mini-erosion. Increased protein concentrations ascribed to inflammation have been shown from day 1 onward. In this study, we assessed the effect of two different extraction pressures on IF sample composition. 相似文献8.
9.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
10.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献